Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

581. Functional diagnostic imaging in epilepsy

Functional diagnostic imaging in epilepsy Functional diagnostic imaging in epilepsy Functional diagnostic imaging in epilepsy Corabian P, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Corabian P, Hailey D. Functional diagnostic imaging in epilepsy. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR HTA (...) Report 10. 1998 Authors' objectives To assess the role of high cost functional diagnostic imaging in routine management of refractory epilepsy. The technologies considered were positron emission tomography (PET), magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG) when used with MRI as magnetic source imaging (MSI). Authors' conclusions Of the functional diagnostic imaging methods considered, only PET has a potential place in routine

1998 Health Technology Assessment (HTA) Database.

582. Vagus nerve stimulation for refractory epilepsy

Vagus nerve stimulation for refractory epilepsy Vagus nerve stimulation for refractory epilepsy Vagus nerve stimulation for refractory epilepsy Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. Vagus nerve stimulation for refractory epilepsy (...) . Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). Technote TN 19. 1998 Authors' objectives To summarise the current status of the use of vagus nerve stimulation (VNS) for refractory epilepsy. Authors' conclusions The available evidence suggests that the role of VNS therapy in the management of refractory epilepsy is yet to be established. Promising clinical evidence, from well-conducted short-term RCTs suggests that VNS therapy is safe and has potential as an adjunctive therapy

1998 Health Technology Assessment (HTA) Database.

583. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. (Abstract)

Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. The use of phenobarbital for childhood epilepsy is controversial because of reported behavioural side-effects; however, whether this research can validly be extrapolated to developing countries is not clear. We undertook a randomised comparison of phenobarbital and phenytoin to assess the acceptability and efficacy of phenobarbital as monotherapy for childhood epilepsy in rural (...) India.Between August, 1995, and February, 1996, 109 unselected children aged 2-18 years with partial and generalised tonic-clonic epilepsy were identified by population screening. 15 families declined to take part. 94 children were randomly allocated treatment with phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily; n = 47) or phenytoin (2.5 mg/kg daily then 5.0 mg/kg daily; n = 47). Children were followed up for 12 months. The primary outcome measure was the frequency

1998 Lancet Controlled trial quality: predicted high

584. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy

Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy Langfitt J T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anterotemporal lobectomy (ATL) for medically intractable complex partial temporal lobe epilepsy. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Hypothetical population with medically intractable complex partial epilepsy. Setting Hospital. The study was carried out at the Strong Memorial Hospital (University of Rochester Medical

1997 NHS Economic Evaluation Database.

585. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy

A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy King J T, Sperling M R, Justice A C, O'Connor M J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anterior temporal lobectomy (ATL) for medically intractable temporal lobe epilepsy. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Patients suffering from medically intractable temporal lobe epilepsy, defined as complex partial or secondarily generalised seizures occurring at a rate

1997 NHS Economic Evaluation Database.

586. Adverse effects in epilepsy therapy: wait and see or go for it?

Adverse effects in epilepsy therapy: wait and see or go for it? Adverse effects in epilepsy therapy: wait and see or go for it? Adverse effects in epilepsy therapy: wait and see or go for it? Deckers C L, Hekster Y A, Keyser A, Lammers M W, Meinardi H, Renier W O Authors' objectives To identify the effects of different approaches to detecting adverse reactions to carbamazepine and valproate during the treatment of epilepsy. Searching MEDLINE was searched from 1991 to 1995. Data from (...) the Nijmegen Epilepsy Research group were also used. Study selection Study designs of evaluations included in the review Studies on carbamazepine and valproate monotherapy were included. The study follow-up time ranged from 11 to 60 months for the studies on carbamazepine, and from 4 to 60 months for the valproate studies. Specific interventions included in the review Oral carbamazepine monotherapy with a mean dose ranging from 450 to 762 mg/day, or a median dose of 600 mg/day. Oral valproate monotherapy

1997 DARE.

587. Feasibility and effects of nurse run clinics for patients with epilepsy in general practice: randomised controlled trial. Epilepsy Care Evaluation Group. Full Text available with Trip Pro

Feasibility and effects of nurse run clinics for patients with epilepsy in general practice: randomised controlled trial. Epilepsy Care Evaluation Group. To test the feasibility and effect of nurse run epilepsy clinics in primary care.A randomised controlled trial of nurse run clinics versus "usual care."Six general practices in the South Thames region.251 patients aged over 15 years who were taking anti-epileptic drugs or had a diagnosis of epilepsy and an attack in the past two years who met (...) specified inclusion criteria and had responded to a questionnaire.Questionnaire responses and recording of key variables extracted from the clinical records before and after the intervention.127 patients were randomised to a nurse run clinic, of whom 106 (83%) attended. The nurse wrote 28 letters to the general practitioners suggesting changes in epilepsy management. For this intervention group compared with the usual care group there was a highly significant improvement in the level of advice recorded

1997 BMJ Controlled trial quality: uncertain

588. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy Hughes D, Cockerell O C Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three antiepileptic drugs for the treatment of intractable partial epilepsy. Type of intervention Secondary prevention. Economic study type This is a cost-minimization analysis. Since no difference in efficacy between the three drugs could be established, then the aim of the study

1996 NHS Economic Evaluation Database.

589. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. (Abstract)

Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. The medical treatment of childhood epilepsy is largely influenced by clinical trials in adult patients. We know of only one randomised comparative trial (of two drugs) in newly diagnosed childhood epilepsy. We have undertaken a long-term, prospective, randomised, unmasked, pragmatic trial of the comparative efficacy and toxicity of four standard

1996 Lancet Controlled trial quality: uncertain

590. An economic evaluation of surgery for temporal lobe epilepsy

An economic evaluation of surgery for temporal lobe epilepsy An economic evaluation of surgery for temporal lobe epilepsy An economic evaluation of surgery for temporal lobe epilepsy Wiebe S, Gafni A, Blume W T, Girvin J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Performing surgery in the treatment of adults with difficult to control temporal lobe epilepsy (TLE). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with difficult to control TLE. Setting Hospital. The economic study was conducted in Ontario, Canada. Dates to which data relate Effectiveness data were collected from studies published between 1965 and 1993. Resource use data related to the period August 1992

1995 NHS Economic Evaluation Database.

591. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. (Abstract)

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lamotrigine has been licensed widely as adjunctive therapy for partial and secondary generalised seizures. Use of the drug as monotherapy was investigated in a double-blind, randomised, parallel-group comparison with carbamazepine in newly diagnosed epilepsy. After 4 weeks of planned, fixed dose escalation, doses were adjusted according to efficacy, adverse (...) (hazard ratio 1.57 [95% CI 1.07-2.31]). Lamotrigine and carbamazepine showed similar efficacy against partial onset seizures and primary generalised tonic-clonic seizures in newly diagnosed epilepsy. Lamotrigine, however, was better tolerated.

1995 Lancet Controlled trial quality: predicted high

592. Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. (Abstract)

Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. The optimal regimen for discontinuing antiepileptic medications in children with epilepsy is unknown.We randomly assigned 149 children to either a six-week or a nine-month period of drug tapering, after which therapy was discontinued. Each group was composed of patients who had been seizure-free for either two or four years before drug tapering was begun. Most patients were (...) ) increased the risk of seizure recurrence.The risk of seizure recurrence during drug tapering and after the discontinuation of antiepileptic drug therapy in children with epilepsy is not different whether the medications are tapered over a six-week or a nine-month period.

1994 NEJM Controlled trial quality: uncertain

593. Cysticercosis as a major cause of epilepsy in Peru Full Text available with Trip Pro

Cysticercosis as a major cause of epilepsy in Peru In countries where cysticercosis is endemic, the proportion of epilepsy due to cysticercosis is not well documented. To investigate the association between cysticercosis and epilepsy, we used the enzyme-linked immunoelectrotransfer blot (EITB) assay to detect serum antibodies to Taenia solium in 498 consecutive outpatients at a neurology clinic in Lima, Peru. Every patient was classified as epileptic (n = 189) or non-epileptic (n = 309) after (...) neurological, and where possible electroencephalographic, examination. A substantially higher proportion of epileptic than non-epileptic patients was seropositive in the EITB (22 [12%] vs 8 [3%], p < 0.001). 19% of epileptic patients born outside Lima, 20% of those with late-onset epilepsy, and 29% of patients with both these characteristics were seropositive. Thus, in Peru, cysticercosis is an important aetiological factor for epilepsy.

1993 Lancet

594. Epilepsy surgery

Epilepsy surgery Epilepsy surgery Epilepsy surgery Sampietro-Colom L, Granados A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sampietro-Colom L, Granados A. Epilepsy surgery. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). 1993 Authors' objectives To provide an overview of the current (...) state of scientific knowledge assessing the safety, efficacy, and related costs of epilepsy surgery. An assessment about the characteristics and amount of current resources (equipment and personnel) in the Catalan hospitals to perform this procedure is made. Also, the criteria to implement an epilepsy surgery program in Catalonia are assessed. Authors' conclusions Epilepsy is a disease associated with social and health care burdens. Drugs are the elective treatment. Nevertheless, 10-20% patients do

1993 Health Technology Assessment (HTA) Database.

595. Prognostic index for recurrence of seizures after remission of epilepsy. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Full Text available with Trip Pro

Prognostic index for recurrence of seizures after remission of epilepsy. Medical Research Council Antiepileptic Drug Withdrawal Study Group. To develop and test a prognostic index for the recurrence of seizures after a minimum remission of seizures of two years in people with a history of epilepsy.Information from a large prospective randomised study of withdrawal of antiepileptic drugs was used to identify clinical and treatment factors of prognostic importance in determining the recurrence (...) sample validation suggested that the model was well calibrated.The model is currently the best available aid for counselling the many patients in the community with epilepsy currently in remission who seek advice about the risks of seizures recurring if they stop antiepileptic drug treatment. The model requires validation in a broad population of patients, and such studies are in progress.

1993 BMJ Controlled trial quality: uncertain

596. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. (Abstract)

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. Valproate is approved for use primarily in patients with absence seizures, but the drug has a broad spectrum of activity against seizures of all types. Partial or secondarily generalized tonic-clonic seizures are often difficult to control adequately with standard

1992 NEJM Controlled trial quality: uncertain

597. Surgery for epilepsy

Surgery for epilepsy Surgery for epilepsy Surgery for epilepsy Silfvenius H, Dahlgren H, Jonsson E, Magnusson S, Marke LA, Norlund A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Silfvenius H, Dahlgren H, Jonsson E, Magnusson S, Marke LA, Norlund A. Surgery for epilepsy. Stockholm: Swedish Council on Technology Assessment in Health Care (...) (SBU) 1991: 95 Authors' objectives To provide an overview of the epidemiology, methods for diagnosis and status of surgical treatment for epilepsy in Sweden and make recommendations. Authors' conclusions In cases where seizures cannot be controlled by medication, neurosurgery is considered. There are no scientifically rigorous studies of surgical treatment for epilepsy, but based on clinical experience, results of surgery are found to be good or very good. Regardless of the type of treatment

1991 Health Technology Assessment (HTA) Database.

598. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group) (Abstract)

Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group) A programme of antiepileptic treatment in a rural and semi-urban region in Kenya was assessed. Patients with generalised tonic-clonic seizures were treated according to one of two simple drug protocols. Health workers screened cases reported by key informants in the community. From the 529 patients identified by health workers (...) therapy. The similarity of these findings to those obtained in newly diagnosed patients in the developed world, the low drop-out rate, the low rate of withdrawal due to adverse effects, and the acceptable compliance with therapy indicate that health workers can monitor therapy adequately. Most patients had had several years of delay before starting therapy for their epilepsy, yet they responded well--a finding that does not support the suggestion that the disorder becomes intractable if not treated

1991 Lancet Controlled trial quality: uncertain

599. Gabapentin in partial epilepsy. UK Gabapentin Study Group. (Abstract)

Gabapentin in partial epilepsy. UK Gabapentin Study Group. Gabapentin is an analogue of gamma aminobutyric acid (GABA) which has anticonvulsant properties in animals. In a multicentre, double-blind, placebo-controlled, parallel-group study of 1200 mg/day gabapentin as additional therapy in 127 patients with drug-resistant partial epilepsy, 25% of patients who received gabapentin had the number of partial seizures at least halved, compared with 9.8% of patients given placebo. The median (...) additional treatment for patients with partial epilepsy refractory to standard therapy, is fairly well tolerated, and appears to have a favourable efficacy-to-toxicity ratio.

1990 Lancet Controlled trial quality: uncertain

600. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. (Abstract)

Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Twenty-four patients with frequent drug-resistant seizures took part in a randomised double-blind placebo-controlled crossover trial of the GABA-transaminase inhibitor, gamma-vinyl GABA. It was added to their usual drug treatment in a dose of 3 g daily. The total number of seizures during the 9-week active treatment period was less than that in the placebo period (p less than 0.001, two-way analysis of variance

1984 Lancet Controlled trial quality: uncertain